CORC

在结果中检索

CORC

浏览/检索结果: 共92条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
L2E: Learning to Exploit Your Opponent 会议论文
意大利 帕多瓦, 2022.07.18-2022.07.23
作者:  Wu Zhe;  Li Kai;  Xu Hang;  Zang Yifan;  An Bo
收藏  |  浏览/下载：19/0  |  提交时间：2022/06/17
The Application of 20 inch MCP-PMT In LHAASO-WCDA 会议论文
Virtual, Berlin, Germany, 2021-07-12
作者:  You, Xiaohao;  Gao, Bo;  Chen, MingJun;  Li, HuiCai;  Liu, Cheng
收藏  |  浏览/下载：18/0  |  提交时间：2023/01/16
Design and expected performances of the large acceptance calorimeter for the HERD space mission 会议论文
Virtual, Berlin, Germany, 2021-07-12
作者:  Pacini, Lorenzo;  Adriani, Oscar;  Bai, Yong-Lin;  Bao, Tian-Wei;  Berti, Eugenio
收藏  |  浏览/下载：33/0  |  提交时间：2022/12/30
Characterizing White Matter Connectivity in Alzheimer's Disease and Mild Cognitive Impairment: Automated Fiber Quantification 会议论文
The Hilton Molino Stucky in Venice, April 8 - 11, 2019
作者:  Dou, Xuejiao;  Yao, Hongxiang;  Jin, Dan;  Feng, Feng;  Wang, Pan
收藏  |  浏览/下载：98/0  |  提交时间：2019/04/23
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：46/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：38/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：30/0  |  提交时间：2019/12/05
Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 会议论文
作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace